Article
Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
International journal of cancer - 20 Dec 1996
Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K
Abstract excerpt
To define the involvement of p16/CDKN2 and p15/MTS2 inactivation in ovarian tumorigenesis and the association of these inactivation events with histological types and clinical stages of ovarian tumors, we analyzed homozygous deletion and somatic mutation of p16/CDKN2 and p15/MTS2 genes, as well a...
Topics
- Carcinoma
- Carrier Proteins
- Cell Cycle Proteins
- Cyclin-Dependent Kinase Inhibitor p15
- Cyclin-Dependent Kinase Inhibitor p16
- Disease Progression
- Enzyme Inhibitors
- Female
- Heterozygote
- Humans
- Mutation
- Neoplasm Staging
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial